By Benjamin Horney ( March 31, 2016, 3:54 PM EDT) -- Medivation Inc., a San Francisco-based biopharmaceutical firm focused on developing drugs that treat cancer, has tapped JPMorgan Chase & Co. to act as adviser as the company fields interest from suitors, Reuters reported on Thursday. Though Medivation does not intend to sell itself, the company has been approached a number of times during the early goings of 2016, the report noted, and the retention of JPMorgan is meant to ensure it is prepared for handling potential proposals. Medivation has a market capitalization of about $6.1 billion, the report noted, and some potentially interested parties could include Sanofi SA, Roche Holding AG and AstraZeneca PLC....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.